<DOC>
	<DOCNO>NCT02586012</DOCNO>
	<brief_summary>Hemophilia A inherited ( genetic ) disease protein , factor VIII ( FVIII ) , promote blood clot miss work properly . Individuals hemophilia A risk bleeding . Bleeding prevent and/or treat recombinant factor VIII ( rFVIII ) , FDA-approved treatment Hemophilia A. Obesity common among patient hemophilia . Some study show obese hemophilia patient may able prevent bleed low dose clot factor dose currently receive . The low dose calculate base patient weigh rather weigh . This clinical research study test whether calculate rFVIII dose base lean body mass ideal body weight ( person weigh base height ) overweight obese patient hemophilia accurate calculate rFVIII dose base person actually weigh .</brief_summary>
	<brief_title>Weight-based Dosing Hemophilia A</brief_title>
	<detailed_description>The investigator propose single center , randomize , control , open-label , crossover trial determine recombinant factor VIII ( rFVIII ) dose accord lean body mass ( LBM ) ideal body weight ( IBW ) achieve target FVIII recovery better precision base total body weight ( TBW ) . The investigator hypothesize use LBM IBW determine dose rFVIII necessary attain desire FVIII recovery 2 +/- 0.2 IU/dl per IU/kg ( 100 +/- 10 % ) overweight obese ( body mass index great equal 25 mg/m2 ) , adult male ( age 18 old ) severe hemophilia A ( FVIII activity le 1 % ) result 50 % great proportion subject within range compare TBW . Eligible patient receive care Hemophilia Center Western Pennsylvania ( HCWP ) enrol clinic visit . Following enrollment completion screen assessment , subject present HCWP three study visit study visit occur successive week . Subjects receive rFVIII period least 72 hour prior study visit . Recombinant FVIII infusion base TBW , LBM , IBW take place study visit , order determine randomization . During study visit , FVIII level assess obtain blood sample 10 30 minute 1 hour infusion . Outcomes include proportion subject achieve desired peak FVIII recovery value 2 +/- 0.2 IU/dl per IU/kg ( 100 +/- 10 % ) 10 minute follow infusion rFVIII dose accord LBM TBW , IBW TBW , LBM IBW . The investigator use mixed effect logistic regression investigate effect use different weight-based dosing method attain target FVIII level .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1 . Adult male age 18 old . 2 . Severe hemophilia A define less 1 % FVIII activity . 3 . Overweight obesity define BMI 25.029.9 â‰¥ 30 mg/m2 , respectively . 1 . Prior history , currently detectable , FVIII inhibitor define great equal 0.6 Bethesda Units ( BU ) ; however , subject past lowlevel nonresponding inhibitor define less 5 BU , increase titer follow FVIII exposure , detectable within 12 month study , despite FVIII exposure period , allow enroll study . 2 . Allergy FVIII product . 3 . Current rFVIII requirement include least 72hour period without rFVIII administration .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>